CEO NeOncoFrax

As part-time CEO of NeOncoFRAx, you will lead the business, financial, and strategic development of a promising initiative in the field of personalized cancer treatment. NeOncoFRAx works together with Erasmus MC on the clinical development of a personalized neoantigen peptide vaccine for patients with pancreatic cancer.

You will be at the intersection of science, clinical development, financing, and entrepreneurship. You will ensure a clear development and financing strategy, maintain relationships with existing and potential financiers and strategic partners, and translate scientific and clinical milestones into a compelling investment story.

In addition, you will work closely with Erasmus MC and Erasmus MC O&O Holding on the further development of NeOncoFRAx. You will monitor governance, financial continuity, and social objectives, and prepare the organization for the next phase of clinical development.

What will you do?

Developing and implementing the financing strategy for IMPRINT-II and the subsequent clinical development steps.

Maintaining relationships with financiers, strategic partners, and other relevant stakeholders.

Guiding and structuring the collaboration with Erasmus MC regarding the clinical development of the vaccine and contributing ideas on the clinical, regulatory, and strategic development route.

Monitoring financial flows, budgeting, reporting, and accountability, as well as the further professionalization and governance of the organization.

Monitoring the social mission of NeOncoFRAx, including broad accessibility and socially responsible pricing, and preparing the organization for the next phase of clinical development following positive results from IMPRINT-II.

The expected time commitment is initially approximately 0.2 FTE, with a possible growth to approximately 0.8 FTE within 24 months, depending on clinical development, financing needs, and further business activities.